全球最大的兩家疫苗公司英國(guó)葛蘭素史克公司和法國(guó)賽諾菲集團(tuán)正合作研發(fā)新冠肺炎疫苗，或?qū)⒃跀?shù)月后開始人體試驗(yàn)。如果試驗(yàn)獲得成功，疫苗將在2021年下半年大量投放市場(chǎng)。

Two of the world’s biggest vaccine companies have joined forces in an “unprecedented” collaboration to develop a Covid-19 vaccine.

世界上最大的兩家疫苗公司展開“前所未有”的合作，聯(lián)手研發(fā)新冠肺炎疫苗。

GlaxoSmithKline and Sanofi, which combined have the largest vaccine manufacturing capability in the world, are working together on a hi-tech vaccine they say could be in human trials within months.

英國(guó)葛蘭素史克公司和法國(guó)賽諾菲集團(tuán)正在合作研發(fā)一種高科技疫苗，這兩家公司加起來擁有世界上最大規(guī)模疫苗生產(chǎn)能力。兩家公司稱，這種疫苗可能在數(shù)月后開始進(jìn)行人體試驗(yàn)。

The pairing is significant because, if successful, the two companies have the capacity to manufacture the hundreds of millions of doses that are likely to be required worldwide.

這一合作意義重大，因?yàn)橐坏┏晒Γ瑑杉夜居心芰ιa(chǎn)出全世界可能需要的數(shù)億劑疫苗。

Emma Walmsley, the chief executive of GSK, described the collaboration as “unprecedented”.

葛蘭素史克首席執(zhí)行官埃瑪·沃姆斯利稱，這一合作“前所未有”。

She said: “What is not common is you’ve got two of the biggest vaccine manufacturers in the world coming together. Both bring significant manufacturing capacity. We believe we’ll be able to make hundreds of millions of doses by the end of next year.”

她說：“世界上最大的兩家疫苗生產(chǎn)商走到一起，這并不常見。二者都會(huì)帶來巨大的生產(chǎn)能力。我們相信，到明年年底，我們將能夠生產(chǎn)出數(shù)億劑（疫苗）。”

Paul Hudson, the chief executive of Sanofi, said: “As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus.”

賽諾菲首席執(zhí)行官保羅·赫德森說：“在世界面臨這一前所未有的全球性衛(wèi)生危機(jī)之際，顯然沒有任何一家企業(yè)能夠單打獨(dú)斗。正因?yàn)槿绱耍愔Z菲將繼續(xù)與葛蘭素史克等同行企業(yè)互相補(bǔ)充專業(yè)技能和資源，目標(biāo)是生產(chǎn)和供應(yīng)足夠數(shù)量的疫苗，從而幫助遏制新冠病毒。”

Sanofi, which is headquartered in France, announced in February that it was entering the race to make a vaccine and had secured support from the US health department.

總部位于法國(guó)的賽諾菲今年2月宣布，它將加入生產(chǎn)疫苗的行列，并已獲得美國(guó)衛(wèi)生部門的支持。

GSK is already offering access to its technology to smaller teams, such as a vaccine effort at the University of Queensland, but this is the first collaboration that would have the ability to rapidly scale up manufacturing.

葛蘭素史克已經(jīng)在向規(guī)模較小的團(tuán)隊(duì)提供技術(shù)，比如澳大利亞昆士蘭大學(xué)的疫苗項(xiàng)目，但與賽諾菲的合作是首次能夠快速提升生產(chǎn)規(guī)模的合作。

Two companies joining forces, rather than competing, in a vaccine effort is extremely unusual, but the urgent need for a Covid-19 vaccine and the potential scale of the market is also not a typical situation.

兩家公司在疫苗研發(fā)領(lǐng)域展開合作而不是競(jìng)爭(zhēng)，這是極其罕見的。不過，對(duì)于新冠疫苗的迫切需求和市場(chǎng)的潛在規(guī)模也并不常見。

The vaccine is based on an existing DNA-based technology that Sanofi uses to make its flu vaccine.

兩家公司合作研發(fā)的這種疫苗將基于賽諾菲用于生產(chǎn)流感疫苗的現(xiàn)有脫氧核糖核酸（DNA）技術(shù)。

When the coronavirus invades the body, immune cells fight back by producing antibodies. These antibodies bind to specific structures on the foreign invader, called the antigen. In the case of Covid-19 the antigen is a spike-like protein on its exterior.

當(dāng)新冠病毒入侵人體時(shí)，免疫細(xì)胞通過產(chǎn)生抗體進(jìn)行反擊。這些抗體會(huì)與外來入侵者身上的特定結(jié)構(gòu)結(jié)合在一起，這些特定結(jié)構(gòu)被稱為抗原。就新冠病毒而言，抗原是其表面的一種刺突狀蛋白。

Sanofi has synthesized a stretch of DNA that encodes the genetic sequence of that protein. When this DNA is inserted into a harmless bacteria in the lab, it churns out little copies of the antigen – but not of the active coronavirus itself– which it hopes will trigger an antibody response, without causing illness.

賽諾菲合成出了一種對(duì)這種蛋白的基因序列進(jìn)行編碼的DNA片段。當(dāng)這段DNA被植入實(shí)驗(yàn)室里的一種無害細(xì)菌時(shí)，它會(huì)產(chǎn)生大量微小的抗原副本，而不是活性新冠病毒本身。賽諾菲希望它們能夠在不引發(fā)疾病的情況下觸發(fā)抗體反應(yīng)。

synthesize[?s?nθ?sa?z]：vt.合成；綜合

GSK is contributing an add-on, known as an adjuvant, that can be mixed in with a vaccine to trigger a stronger immune reaction. The same technology was used in the H1N1 flu pandemic.

葛蘭素史克將貢獻(xiàn)一種被稱為佐劑的附加物質(zhì)。它可以與疫苗混合，引發(fā)更加強(qiáng)烈的免疫反應(yīng)。這種技術(shù)也曾應(yīng)用于甲型H1N1流感的疫苗研發(fā)。

adjuvant['?d??v(?)nt]：n.佐藥；輔助物

On Tuesday, Walmsley said GSK would not profit from the vaccine during the pandemic and that any revenue would be reinvested in scaling up manufacturing and into research on pandemic preparedness.

本周二（4月14日），沃姆斯利表示，葛蘭素史克不會(huì)在新冠疫情期間從疫苗中獲利，所有收入都將用于擴(kuò)大生產(chǎn)規(guī)模和疫情應(yīng)對(duì)相關(guān)研究。

The companies plan to start phase one trials in the second half of this year and, if successful, say the vaccine could be widely available by the second half of 2021.

兩家公司計(jì)劃在今年下半年開始第一階段臨床試驗(yàn)，并表示，一旦試驗(yàn)取得成功，這種疫苗可能會(huì)在2021年下半年大量投放市場(chǎng)。

來源：衛(wèi)報(bào)、參考消息網(wǎng)

編輯：yaning